mammalian cell line development

CHO Plus was founded in 2014 to address the high costs and capacity issues facing therapeutic protein manufacturers. It has developed patented technology for creating highly productive, GMP-compliant mammalian cell lines used for the production of therapeutic proteins and viruses, demonstrating a 10-fold protein productivity increase versus parent cells in a model system. The company plans to license its technology to and collect royalties from biopharmaceutical companies.

Read more

cell engineeringgenome transcription hotspot technologytechnology licensing

Curia is a global contract research, development and manufacturing organization (CDMO) with over 30 years of experience guiding clients through drug discovery, development, and manufacturing. It offers services across Small Molecule, Generic APIs, Sterile Drug Product, and Biologics, operating an integrated network of 20+ facilities and 3,000+ professionals across North America, Europe, and India.

Read more

analytical testingantibody discovery and engineeringchemical process R&Ddownstream process developmentdrug discoveryfermentationflow chemistryGMP manufacturinghigh potency API (HPAPI) manufacturingLNP formulationmRNA process developmentrecombinant antibody productionrecombinant protein productionsterile API manufacturingupstream process development